VRCI Stock Price, Chart, Stats & News

Verici Dx plc
Save
Verici Dx plc (VRCI) does not currently pay a dividend.
3.76M
Market cap
–
Current P/E
–
Forward P/E
VRCI chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Medical - Diagnostics & Research
Industry
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure.
Similar securities
Based on sector and market capitalization
Report issue





